Compare Futu Holdings Ltd (FUTU) vs Summit Therapeutics Inc (SMMT) Price & Performance

Futu Holdings Limited (FUTU) trades at $105.31, down 3.12% on the day. The stock shows strong fundamentals with a P/E of 11.63 and robust profitability, including a net income margin of 41.83% and ROE of 28.09%. Revenue grew to $22.85B in 2025, and cash flow from operations surged to $31.0B in 2024. Technical indicators are bullish, with moving averages supporting an uptrend and key support at $103. However, recent earnings misses and a securities class action lawsuit pose significant headwinds.

The outlook for FUTU is mixed; strong financial health and analyst consensus leaning buy (58.34%) suggest potential upside, but legal risks and earnings volatility require caution. Investors should weigh solid fundamentals against regulatory and litigation overhangs that could impact near-term performance.

Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.

The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.